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The association of the cytoplasmic domains of
interleukin 4 receptor alpha and interleukin
13 receptor alpha 2 regulates interleukin 4 signaling
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Interleukin-4 (IL-4) and Interleukin-13 (IL-13), key cytokines in the pathogenesis of allergic inflammatory
disease, mediate their eﬀects via a receptor composed of IL-13Ra1 and IL-4Ra. A third (decoy) receptor
called IL-13Ra2 regulates interleukin signaling through this receptor complex. We employed a variety
of biophysical and cell-based techniques to decipher the role of this decoy receptor in mediating IL-4
signaling though the IL-4Ra–IL-13Ra1 receptor complex. Surface plasmon resonance (SPR) analysis
showed that IL-13Ra2 does not bind IL-4, and does not affect binding of IL-4 to IL-4Ra. These results
indicate that the extracellular domains of IL-4Ra and IL-13Ra2 are not involved in the regulation of IL-4
signaling by IL-13Ra2. We next used a two-hybrid system to show that the cytoplasmic domains of
IL-4Ra and IL-13Ra2 interact, and that the secondary structure of the IL-13Ra2 intracellular domain is
critical for this interaction. The cellular relevance of this interaction was next investigated. BEAS-2B
bronchial epithelial cells that stably express full length IL-13Ra2, or IL-13Ra2 lacking its cytoplasmic
domain, were established. Over expression of IL-13Ra2 attenuated IL-4 and IL-13 mediated STAT6
phosphorylation. IL-13Ra2 lacking its cytoplasmic domain continued to attenuate IL-13-mediated signaling,
but had no effect on IL-4-mediated STAT6 signaling. Our results suggest that the physical interaction
between the cytoplasmic domains of IL-13Ra2 and IL-4Ra regulates IL-4 signaling through the IL-4Ra–IL-13Ra1
receptor complex.
Introduction
Interleukin 4 (IL-4) and Interleukin 13 (IL-13) play important
roles in the pathogenesis of asthma and other atopic diseases by
inducing the expression of adhesion molecules, cytokines and
chemokines, such as vascular cell adhesion molecule (VCAM)-1
and monocyte chemoattractant protein-1 (MCP-1), which direct
the migration of T lymphocytes, monocytes, basophils and
eosinophils to inflammation sites.1–3 In asthma, IL-4 and IL-13
act on bronchial epithelial cells and fibroblasts to induce
eotaxin, which is an eosinophil chemoattractant and inhibitor of
eosinophil apoptosis, to promote allergic airway inflammation.4,5
IL-4 and IL-13 also induce epithelial mucin gene expression
and promote goblet cell hyperplasia, leading to mucus plugging
and airflow obstruction.6,7
IL-13 mediates its eﬀects via its cognate receptor, a hetero-
dimer composed of the IL-13 binding protein, IL-13Ra1 and the
Interleukin-4 receptor a chain (IL-4Ra).8–10 The IL-13Ra1–IL-4Ra
complex also acts as a receptor for IL-4, especially in cells lacking
the common gamma chain (gc) that usually forms a complex with
IL-4Ra to bind IL-4.11,12 Binding of either IL-13 or IL-4 to the
IL-13Ra1–IL-4Ra receptor complex initiates a phosphorylation
cascade that results in STAT6 dimerization; STAT6 then translocates
to the nucleus where it induces inflammatory gene expression.
A second IL-13 receptor, IL-13Ra2, has been identified that
shares 37% homology with IL-13Ra1 and binds IL-13 with high
aﬃnity but it does not bind IL-4.13,14 Traditionally IL-13Ra2
has been thought of as a decoy receptor that sequesters IL-13
from its signaling receptor complex, IL-13Ra1–IL-4Ra.13–15
Consistent with this, IL-13Ra2 has been shown to have the
characteristics of a negative regulator, with a fast association
rate but an exceptionally slow dissociation rate.16 IL-13Ra2 has
a short cytoplasmic tail that lacks any obvious signaling motif
and is unable to initiate a signal through the STAT6 pathway.
However it has been reported that glioblastoma cells express
abnormally high levels of IL-13Ra2 that serve to inhibit IL-4
signaling and overcome IL-4 mediated growth arrest.17 While
this initial work suggested a potentially aberrant role for
IL-13Ra2 in malignancy, the levels of IL-13Ra2 on the surface
of primary bronchial fibroblasts have been found to be inversely
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correlated to their responsiveness not only to IL-13, but also to
IL-4.18,19 These observations highlighted a previously unrecog-
nized role for IL-13Ra2 in normal cell function. As in the
glioblastoma cells, IL-13Ra2 was found to be associated with
IL-4Ra when the fibroblasts were treated with IL-4, suggesting
that a physical interaction between IL-13Ra2 and IL-4Ra was
also required for this regulatory mechanism. Although the
original studies17 suggested that the cytoplasmic tail of IL-13Ra2
is required for inhibition of IL-4 signaling, extracellular binding
of neutralizing antibodies to IL-13Ra2 can also prevent the
inhibition of IL-4-stimulated responses by IL-13Ra2 in bronchial
fibroblasts.20,21 This may be a result of the antibody causing
steric hindrance around IL-13Ra2, blocking its interaction with
IL-4Ra, but it remains unclear whether IL-13Ra2 exerts its
regulatory effect on the binding of IL-4 to IL-4Ra via interaction
of the extracellular domains of the two receptors, or via the
interaction of the cytoplasmic domains of IL-4Ra and IL-13a2.
Here we employ a variety of in vitro and cell-based techniques to
examine the physical interaction of both the extracellular and
cytoplasmic domains of IL-13Ra2 and IL-4Ra, to gain a better
understanding of the molecular mechanism of regulation of IL-4
signaling by IL-13Ra2.
Material and methods
DNA synthesis and sequencing was carried out by Eurofins
MWG Operon. All restriction endonucleases were purchased
from New England Biolabs; T4 DNA ligase was purchased from
Promega. All other molecular biology reagents were purchased
from New England Biolabs, Fisher Scientific or Promega and
were used as directed by the manufacturer. Chemical reagents
were purchased from Sigma Aldrich, Fisher Scientific or Merck
and were used as received. DNA purification was carried out
using QIAquick PCR Purification Kits and plasmid purification
was carried out using QIAGEN Plasmid Mini Kit (QIAGEN). The
fidelity of all generated plasmids was verified by sequencing.
The CRIM plasmids pAH68 and pAH69 were obtained from the
E. coli Genetic Stock Centre at Yale University, USA. Surface
plasmon resonance (SPR) measurements were carried out with
a BIAcore 2000. CM5 sensor chips, HBS buﬀer (10 mM Hepes
with 150 mM NaCl, 3.4 mM EDTA and 0.005% surfactant P20),
amine coupling kit and regeneration agents were supplied by
GE Healthcare, unless otherwise stated. Recombinant soluble
human IL-13Ra2/IgG1 chimera (shIL-13Ra2.Fc) and shIL-4Ra.Fc
were obtained from R&D Systems. Recombinant IL-13 and IL-4
were purchased from Peprotech. SDS-PAGE reagents were from
Amersham Life Sciences. Transfection regents were obtained
from Qiagen.
Surface plasmon resonance (SPR) measurements
The molecular interactions between shIL-13Ra2.Fc, shIL-4Ra.Fc
and IL-4 or IL-13 were determined by SPR measurements22–24
using a BIAcore 2000t biosensor as previously detailed.16 shIL-
4Ra.Fc and or shIL-13Ra2.Fc was diluted in HBS running buffer
(10 mMHepes, pH 7.4, 150 mMNaCl, 3.4 mM EDTA and 0.005%
surfactant P20) and coupled to a CM5 sensor chip surface using
the manufacturer’s protocol. IL-4 and IL-13 were diluted
from stock to the desired concentration (200, 400, 600, 800 or
1000 nM) in HBS buffer. To determine kinetic constants,
sensograms were collected at 25 1C, flow rate 50 ml min1 and
data collection rate of 1 Hz. Sensograms were recorded and
normalised to a base line of 0 resonance units (RU). Equivalent
concentrations of each protein were injected over an untreated
surface to serve as blank sensograms for subtraction of
bulk refractive index background. The sensor chip surface
was regenerated between runs with a 1 minute injection of
10 mM HCl, at 10 ml min1. The resultant sensograms were
evaluated using the BIA evaluation 2.0 software to provide
kinetic data.
Construction of IL-4Ra–IL13-aR2 bacterial reverse two-hybrid
systems (RTHS)
The cytoplasmic domain of IL-4Ra was amplified by PCR and
cloned into pTHCP1425 using KpnI and XhoI restriction endo-
nucleases to give pTHCP14-IL-4Ra. The cytoplasmic tail of
IL-13Ra2 was amplified by PCR and cloned into pTHCP14-IL-4Ra
with SalI and SacI restriction endonucleases to give plasmid
pTHCP14-IL-4Ra–IL-13Ra2. The cassettes encoding IL-4Ra.P22
and IL-13Ra2.434 fusion proteins were integrated onto the
chromosome of E. coli strain SNS12625 using plasmids pAH68
and pAH6926 as previously described27,28 to give the IL-4Ra–IL-
13Ra2 RTHS. The IL-4Ra–IL-13Ra2P366A RTHS was generated by
site-directed mutagenesis (SDM), cloned into pTHCP14-IL-4Ra–
IL-13Ra2 with AgeI and SacI. The IL-4Ra–IL-13Ra2P374A RTHS
was generated by SDM, and cloned into pTHCP14-IL-4Ra–IL-
13Ra2 with SalI and HindIII. The IL-4Ra–IL-13Ra2P366A,P374A
RTHS was generated as above, except IL-13Ra2 was amplified
by PCR using the forward and reverse mutagenic primers used
for the P366A and P374A mutants, and cloned into pTHCP14-
IL-4Ra–IL-13Ra2 with AgeI and HindIII. Protein–protein inter-
actions in the RTHS were assessed as below.
ortho-Nitrophenyl-b-galactosidase (ONPG) assays and drop
spotting
Protein–protein interactions were assessed by ONPG assay
and drop spotting as previously detailed.29,30 Briefly, for ONPG
assays, overnight culture of each RTHS were subcultured and
incubated at 37 1C for 2 h with shaking to OD600 of 0.5–0.7.
IPTG was then added to a final concentration of 0, 2.5, 5, 10, 15,
25, 50, 100, and 250 mM and the cultures incubated for a further
1 h at 37 1C. The OD600 was recorded for all the samples before
ONPG assays were conducted using a standard protocol. For
drop-spotting, 2 ml of overnight cultures of each RTHS were
diluted in 10% glycerol solution and ten-fold serial dilutions
prepared in a sterile 96-well plate for each strain. 2.5 ml of each
dilution was drop-spotted onto selective plates (200 ml Agar,
25 ml minimal media A, 10 ml 50% glycerol, 250 ml 1 MMgSO4,
50 mg ml1 Ampicillin and 25 mg ml1 Spectinomycin), containing
25 mg ml1 Kanamycin, 2.5 mM 3-amino-1,2,4-triazole, with or
without 25 mM IPTG. Each strain was also spotted on LB-agar,
supplemented with 100 mM IPTG, to demonstrate that the
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STAT6 phosphorylation
BEAS-2B cells over expressing IL-13Ra2 or IL-13Ra2 cytoplasmic
mutations were established. Briefly, IL-13Ra2 was amplified
by PCR from cDNA using the following primers: Forward
GTTGTTCTCGATGGCTTTCGTTTGGC and Reverse GTTGGTAG
CTTTCATGTATCACACAGAAAAATTCTGG. The PCR product was
digested and cloned in pcDNA3.1(–) vector (Invitrogen Paisley,
UK). Receptor expression was confirmed by Flow Cytometry.
Cells were grown to confluence before treatment with IL-4 or
IL-13 (10 ng ml1) for 60 minutes in the absence or presence of
an IL-13Ra2 neutralising Ab (10 mg ml1). The cells were then
solubilised in boiling SDS sample buffer before being subjected
to SDS-PAGE and western Blotting with a phospho-STAT6 anti-
body (Cell Signaling Technology), using a pan STAT6 antibody
as loading control, as described previously.20
Results
Kinetic analysis of IL-4 binding to the extracellular domain of
IL-4Ra
The role of the interaction of the extracellular domains of
IL-4Ra with IL-13Ra2 on interleukin signaling mediated through
the IL-4Ra–IL-13Ra1 receptor was assessed by SPR. The binding
of IL-4 and IL-13 to IL-4Ra was evaluated with soluble human
IL-4Ra/IgG1 chimera (shIL-4Ra.Fc) immobilised onto a CM5
sensor chip surface. The dissociation constant (KD = koff/kon) for
IL-4 binding to shIL-4Ra.Fc was calculated to be 412  81 pM
(Fig. 1A, data represents mean  S.D, n = 10 for all values
quoted). As expected, IL-13 did not bind shIL-4Ra.Fc (Fig. 1B),
but bound soluble human IL-13Ra2/IgG1 chimera (shIL-13Ra2.Fc)
immobilised onto a sensor chip surface with a KD of 1.96 1.7 nM.
To assess the effect of the interaction of the extracellular
domains of IL-4Ra and IL-13Ra2 on IL-4 signaling, 1200 RU
hIL-4Ra and 600 RU shIL-13Ra2 were immobilised to the sensor
chip surface. The presence of shIL-13a2.Fc had no significant
effect on the binding of IL-4 to IL-4Ra (KD = 402  87 pM,
Fig. 1C). Increasing the concentrations of shIL-13Ra2.Fc to
1800 RU did not affect the binding of IL-4 to shIL-4Ra.Fc
(KD = 400  130 pM). IL-4 did not bind to shIL-13Ra2.Fc
immobilised onto a CM5 sensor chip. IL-13 bound the mixture
of 1200 RU hIL-4Ra and 600 RU shIL-13Ra2 with a KD of
2.10  1.6 nM (Fig. 1D), and the mixture of 1200 RU hIL-4Ra
and 1800 RU shIL-13Ra2 with a KD of 1.82  2.2 nM. These data
extend our previous studies,11,18 demonstrating that IL-13Ra2
binds IL-13, but is neither able to sequester IL-4 from its cognate
receptor (IL-4Ra), nor to antagonize this interaction. The KD values
obtained by SPR for the IL-4:IL-4Ra interaction are comparable to
those previously observed in cell-based assays.31,32
Two-hybrid analysis of the association of IL-4Ra and IL-13Ra2
cytoplasmic domains
The above SPR data demonstrates that while the extracellular
domain IL-13Ra2 directly competes with IL-13Ra1 for IL-13,
it does not aﬀect the binding of IL-4 to IL-4Ra. We therefore
turned our attention to assessing the role of the cytoplasmic
domain of IL-13Ra2 in regulating the IL-4 signaling through
IL-4Ra. As the cytoplasmic domain of IL-13Ra2 is relatively small
and not ideal for binding studies using SPR, we used a bacterial
reverse two-hybrid system (RTHS) to evaluate whether there was
a direct interaction between the cytoplasmic domains of IL-4Ra
and IL-13Ra2. The bacterial RTHS is based on the bacterio-
phage regulatory system, using chimeric repressor fusions and
promoter sequences to link the interaction of targeted fusion
protein heterodimers to the expression of three reporter
genes; HIS3 (imidazole glycerol phosphate dehydratase) and
KanR (aminoglycoside 30-phosphotransferase for kanamycin
resistance) are two chemically-tunable, conditionally selective
reporter genes.25,27 The third reporter gene, LacZ (b-galactosidase)
is used to quantify the protein–protein interaction through
b-galactosidase assays. An E. coli RTHS strain was constructed
that chromosomally expressed the cytoplasmic domain of
IL-13Ra2 as an N-terminal fusion with the 434 phage repressor
domain, and the cytoplasmic domain of IL-4Ra as an N-terminal
fusion with the chimeric P22 phage repressor domain (both
regulated by IPTG via a Ptac promoter). Interaction of the
targeted proteins (IL-13Ra2 with IL-4Ra) brings together the
434 and P22 repressor domains, forming a functional repressor
that binds onto the corresponding operator regions upstream
of the three reporter genes (on the chromosome of the RTHS
strain), and prevents transcription of the reporter genes (Fig. 2A).
This results in the host strain being unable to survive or grow
on selective media lacking histidine and containing kanamycin,
in an IPTG-dependent manner.
We initially used o-nitro-b-galactosidase (ONPG) assays to
determine if the cytoplasmic tail of IL-13Ra2 interacted with
Fig. 1 SPR analysis of IL-4 and IL-13 binding to IL-4Ra and IL-13Ra2. Represen-
tative blank-corrected sensograms; concentration used lower to upper curve is
200, 400, 600, 800 and 1000 nM (A) IL-4 binds IL-4Ra with a KD of 412  81 pM.
(B) IL-13 does not bind IL-4Ra. (C) Binding of IL-4 to IL-4Ra is not aﬀected by the
presence of IL-13Ra2; KD = 402  87 pM. (D) IL-13 binds the immobilised mixture
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the intracellular domain of IL-4Ra. A RTHS strain containing
only the repressor domains was used as a negative control.
A dose dependent decrease of b-galactosidase activity was
observed in the ONPG assays with increasing IPTG concen-
tration with the IL-13Ra2–IL-4Ra RTHS; increasing IPTG levels
had no effect on the b-galactosidase activity of the negative
control RTHS strain (Fig. 2B). The formation of a functional
repressor in the IL-13Ra2–IL-4Ra RTHS strain was further
demonstrated by drop-spotting ten-fold serial dilutions of this,
and the control RTHS strain onto selective plates without
or with 25 mM IPTG. The negative control strain showed full
growth on selective media regardless of IPTG levels, whereas
the growth of the IL-13Ra2–IL-4Ra RTHS was significantly
affected by the presence of IPTG (Fig. 2C, 6 spots of growth
in the absence of IPTG versus 1 spot of growth in the presence
of 25 mM IPTG). The possibility that the IPTG-dependent loss
of growth was due to toxicity of the fusion proteins to the host
strain was probed by repeating this experiment on LB-agar plates.
No IPTG-dependent repression of growth was observed indicating
that the loss of b-galactosidase activity and the inability to survive
on selective media is due to dimerization of the cytosolic
domains of IL-13Ra2 with IL-4Ra.
As an additional control, we sought to assess the importance
of the secondary structure of the cytoplasmic tail of IL-13Ra2
for the observed interaction. We sought key residues to mutate,
but analysis did not reveal structural motifs typical of a
regulatory domain, however the sequence (amino acids 364–380,
RKPNTYPKMIPEFFCDT) contains three proline residues. Prolines
are known to confer structural rigidity to peptide chains, and
proline-rich motifs have been extensively demonstrated to be
critical to protein–protein interactions.33 We therefore hypo-
thesized that the loss of these proline residues would affect the
interaction of IL-13Ra2 with IL-4Ra. In order to probe this
hypothesis, we used the de novo peptide structure prediction
software PepFold,34–36 which has been specifically designed for
short amino acid sequences. The structures predicted by PepFold
suggested that the secondary structure of the cytoplasmic tail of
IL-13Ra2 would be significantly altered by mutation of proline
residues 366 and 374 to alanine (Fig. 2D and E). To determine
whether the predicted structure change would affect the inter-
action between IL-13Ra2 and IL-4Ra cytoplasmic tails, a double
pointmutant IL-13Ra2P366A,P374A–IL-4RaRTHS strain was generated.
This strain did not show IPTG-dependent loss of b-galactosidase
activity in ONPG assays (Fig. 2B), and the growth of this strain on
minimal media was also not inhibited by IPTG (Fig. 2B), suggesting
that the cytoplasmic domains of IL-13Ra2P366A,P374A and IL-4Ra
do not interact. In addition, single point mutants RTHS were
generated; IL-13Ra2P366A–IL-4Ra RTHS and IL-13Ra2P374A–IL-4Ra
did not show any IPTG-dependent inhibition of growth (Fig. 2C)
demonstrating that mutation of either proline 366 or 374 to
alanine is sufficient to disrupt this interaction. This may be due
to elimination of a recognised proline-rich binding motif, or a
result of changes in secondary structure that result from these
point mutations.
The role of the cytoplasmic domain of IL-13Ra2 in regulating
IL-4 signaling in cells
To assess the biological significance of the identified interaction
of the cytoplasmic domains of IL-13Ra2 and IL-4Ra, and its
aﬀect on IL-4 signaling, two BEAS-2B cell lines (human bronchial
epithelium) were established; one stably expressing full length
IL-13Ra2 receptor (BEAS-2B-FL) and the other expressing the
IL-13Ra2 receptor without its cytoplasmic domain (BEAS-2B-NT).
These cells were treated with IL-13 or IL-4 for 30 min before
being solubilized and prepared for Western blotting. Over
expression of full length or truncated IL13Ra2 led to the inhibition
of IL-13 stimulated STAT6 phosphorylation (Fig. 3). The addition
of an IL-13Ra2 neutralising antibody restored IL-13 signaling
via STAT6 in both transfected cells lines (Fig. 3) suggesting
that IL13Ra2 directly competes with IL13Ra1 for IL-13 binding,
Fig. 2 Assessing the interaction of IL-4Ra and IL-13Ra2 cytoplasmic domains. (A) In the bacterial RTHS, the expression of the P22-IL-4Ra and 434-IL-13Ra2 fusion
proteins is induced by IPTG; if IL-4Ra and IL-13Ra2 interact, they will bring together P22 and 434 to form a functional repressor that prevents expression of the
downstream reporter genes, thus preventing survival and growth on minimal media. (C) Drop-spotting serial dilutions (2.5 mL ofB10n cells per ml) of the blank and
IL-4Ra–IL-13Ra2, RTHS onto selective media plates with and without IPTG. A significant reduction in growth is observed for the IL-4Ra–IL-13Ra2 RTHS upon induction
of protein expression with IPTG, indicating formation of a functional repressor, but not for the blank. This interaction is not observed for mutant IL-13Ra2P366A,
IL-13Ra2P374A, or IL-13Ra2P366A,P374A receptors. (D) Prediction of the structure of the cytoplasmic domain of IL-13Ra2 with the de novo peptide structure prediction
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with IL-13Ra2 simply acting as a decoy receptor by sequestering
IL-13 from IL-13Ra1 with no requirement for the cytoplasmic
domain.
In cells treated with IL-4 however, inhibition of STAT6 phos-
phorylation was only observed in cells expressing full length
IL13Ra2; STAT-6 phosphorylation was not aﬀected in cells
expressing the truncated IL13Ra2 (Fig. 3). This points to a key role
for the cytoplasmic tail of IL-13Ra2 in modulating IL-4 response.
Furthermore, as previously described,20,21 an IL-13Ra2 neutralising
antibody restored STAT6 signaling in BEAS2B-FL cells treated with
IL-4. As our SPR data demonstrates, this is not due to the antibody
preventing IL-13Ra2 binding IL-4, but likely a result of additional
extracellular steric hindrance preventing assembly of the IL-4Ra–IL-
13Ra2 receptor complex, and the resulting association of their
cytoplasmic domains.
We attempted to explore the cellular eﬀect of mutating the
proline residues in the cytoplasmic domain of IL-13Ra2 (identified
as important for the protein–protein interaction by two-
hybrid analysis) by establishing cell lines that stably expressed
IL-13Ra2P366A, IL-13Ra2P374A IL-13Ra2P366A,P374A. However, we
were unable to obtain significant levels of receptor expression
in the resulting cell lines to draw meaningful conclusions. It is
possible that the introduced mutations in the cytoplasmic
domain of IL-13Ra2 compromise its insertion into the cell
membrane, and/or leave the mutant receptor vulnerable to
protease attack.33
Discussion
The cytoplasmic domain of IL-13Ra2 is composed of only
17 amino acids,37 and therefore may have been viewed as having
little eﬀect on the modulation of interleukin signalling by this
receptor. This is true in the case of IL-13 signaling, however,
our data suggests that the cytoplasmic tail of IL-13Ra2 plays a
key role in modulating IL-4 signaling through its interaction
with the cytoplasmic tail of IL-4Ra. One possible mechanism is
that the IL-13Ra2 cytosolic domain interferes with the associa-
tion or activation of signaling molecules, which in turn prevent
downstream signal cascades. The intracellular domain of IL-4Ra
contains a membrane proximal Box-1 sequence that serves as a
docking site for JAK1. It would be reasonable to speculate that the
regulation of IL-4 signaling by IL-13Ra2 occurs via this site, as it is
situated close to the membrane and therefore is in close proximity
to the cytoplasmic domain of IL-13Ra2 when the two receptors
associate.38 As the phosphorylation cascade that leads to activation
of STAT6 is initiated by JAK1, blocking the interaction of this
signaling molecule with its receptor complex would completely
inhibit the entire STAT6 signaling pathway. A similar mechanism
has been linked to the abnormal proliferation of glioblastoma
cells, in which IL-4-mediated antitumor activity in rodent experi-
mental gliomas is abrogated by aberrant expression of IL-13Ra2 by
the glioblastoma cells.17 Furthermore, although glioblastoma cells
fail to express the alternative IL-4Ra/common g chain receptor
complex, this form of the IL-4 receptor is present on both epithelial
cells and fibroblasts, suggesting that IL-13Ra2 may have the ability
to inhibit IL-4Ra in either signaling receptor complex. The data
from our RTHS experiments suggest that mutation or deletion of
one or more of the proline residues lead to a loss of association
between IL-4Ra and IL-13Ra2. These results imply that conforma-
tional features may be important in the regulatory mechanism of
IL-4, with this domain providing a rigid structure that blocks
docking of JAK1 to IL-4Ra. In glioblastoma cells, the upregulation
of IL-13Ra2 leads to the activation of STAT3, although this eﬀect
does not require a direct physical interaction between STAT3 and
IL-13Ra2. A hypothesis consistent with these observations is that
the role of IL-13Ra2 in IL-4 signaling is to regulate the STAT6
pathway, thus reducing inflammation, whilst initiating the STAT3
pathway which in the case of fibroblasts would lead to survival and
an enhancement of fibrotic responses.
The work here has utilized a variety of biochemical and cell-
based techniques to demonstrate the significant role played by
the cytoplasmic tail of IL-13Ra2 in regulating IL-4 signaling.
The IL-4/IL-13 pathway is an extremely important mediator of
inflammatory responses. Thus a complete understanding of
how IL-13Ra2 regulates these two important cytokines may lead to
the development of a novel therapy for asthma or other inflam-
matory conditions that selectively targets these cytokines.
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